The irAEs associated with the combination therapy included colitis, hepatitis, pneumonitis, and endocrinopathies such as hypophysitis, which occur at substantially higher rates compared to those seen with PD-1 inhibitors alone. The gene discussed is PDCD1; the disease is Hepatitis.